Straits Times Index
3,015.86+1.08(+0.04%)Nikkei
28,864.32-65.79(-0.23%)Hang Seng
29,133.65-103.14(-0.35%)
bluebird bio, Inc. (BLUE)
| Previous close | 29.34 |
| Open | 29.10 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 800 |
| Day's range | 27.63 - 29.56 |
| 52-week range | 24.24 - 72.51 |
| Volume | 1,799,979 |
| Avg. volume | 2,062,735 |
| Market cap | 1.876B |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.95 |
| Earnings date | 10 May 2021 - 14 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 46.53 |
- Business Wire
Breaking Notice: Rosen, a Globally Recognized Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – BLUE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020, inclusive (the "Class Period") of the important April 13, 2021 lead plaintiff deadline.
- Business Wire
bluebird bio to Present at Cowen Health Care Conference
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET.
- Business Wire
The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLUE) and Bristol Myers Squibb’s (NYSE: BMY) investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121), in adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, were published today in The New England Journal of Medicine.1
